Core Viewpoint - The beauty company, Giant Biological (02367.HK), is experiencing significant growth in performance and market capitalization, surpassing HKD 80 billion, while facing public scrutiny regarding the collagen content in its products [1][10]. Company Summary - Giant Biological's product, "Kefumei Recombined Collagen Protein Essence," was criticized by a beauty industry influencer for allegedly having a collagen content of only 0.0177%, which does not meet the regulatory requirement of being above 0.1% for non-trace ingredients [1][4]. - In response to the allegations, Giant Biological stated that their testing showed collagen content exceeding 0.1% and has engaged third-party testing agencies to verify the results [6][10]. - The company has seen its stock price and market value rise despite the controversy, indicating strong investor confidence [1][10]. Industry Summary - The controversy surrounding recombinant collagen products has sparked discussions about the effectiveness and labeling of such ingredients in the beauty industry [7][9]. - The market for recombinant collagen products is projected to grow significantly, with an expected market size of RMB 108.3 billion by 2027, and a compound annual growth rate of 55% from 2022 to 2027 [10]. - Major players in the beauty industry, including Marubi Biological and Huaxi Biological, are also entering the recombinant collagen market, indicating a competitive landscape [10].

Core Viewpoint - The article discusses the controversy surrounding Huaxi Biological, a leading player in the medical aesthetics industry, which publicly refuted claims made by nine brokerage firms regarding the obsolescence of hyaluronic acid, asserting that these claims mislead the market and harm the industry [2][5][13]. Group 1: Industry Response - Huaxi Biological received support from two industry associations before making its statement and has reported the misleading content to the China Securities Regulatory Commission (CSRC) [2][12]. - Following Huaxi's public rebuttal, some brokerage firms have deleted their reports, and certain institutions have issued apologies to the company [2][12]. - The brokerage reports in question were primarily focused on the emerging concept of recombinant collagen, which Huaxi argues is being promoted at the expense of hyaluronic acid [5][13]. Group 2: Misleading Claims - Huaxi Biological criticized the brokerage reports for making misleading comparisons between hyaluronic acid and recombinant collagen, claiming that these reports lacked scientific basis and were driven by speculative capital [5][13]. - The company highlighted that the reports suggested hyaluronic acid was inferior to recombinant collagen in terms of safety and efficacy, which Huaxi disputes, stating that such conclusions are not supported by scientific evidence [5][31]. Group 3: Regulatory and Compliance Issues - The article raises concerns about the compliance of the brokerage reports, suggesting that they may not have adhered to the necessary standards for objectivity and scientific backing [20][21]. - Industry experts indicate that the reports should have included relevant data to support their claims, and the lack of such data could lead to regulatory scrutiny [21][22]. - The ongoing regulatory environment is described as increasingly stringent, with past instances of penalties for brokerage firms due to similar issues [26][27]. Group 4: Scientific Basis of Claims - Huaxi Biological argues that both hyaluronic acid and recombinant collagen have their unique applications and benefits, and it is inappropriate to declare one superior to the other without substantial scientific evidence [31][32]. - The company emphasizes that the existing research favors hyaluronic acid in certain applications, particularly in skin hydration and immediate filling, while recombinant collagen may have advantages in tissue repair [31][32].

Core Viewpoint - The article discusses the controversy surrounding Huaxi Biological's rebuttal of the claims made by nine brokerage firms regarding hyaluronic acid being "outdated" and the promotion of recombinant collagen as a superior alternative, highlighting the impact of these claims on the market and the industry [2][4][9]. Group 1: Company Actions - Huaxi Biological publicly refuted the claims about hyaluronic acid and named nine brokerage firms for misleading reports, which has led to some brokerages retracting their reports and issuing apologies [2][8]. - The company received support from two industry associations before making its statement and has reported the matter to the China Securities Regulatory Commission [2][8]. - As of May 23, three of the ten reports mentioned have been removed from public access, while the remaining seven are still available for viewing [8][9]. Group 2: Industry Context - The medical beauty industry is characterized by a high overlap between capital market participants and enterprise users, making capital evaluations significantly impactful on the competitive landscape, which explains Huaxi Biological's strong response [2][4]. - The article emphasizes that the claims made in the brokerage reports lack scientific basis and are driven by speculative capital, which could harm a key industry in China [6][9][24]. Group 3: Scientific Claims - Huaxi Biological argues that the reports promoting recombinant collagen over hyaluronic acid are misleading and lack substantial scientific evidence, asserting that both substances have their unique benefits and should not be directly compared [23][24]. - The company highlights that the regulatory approvals for hyaluronic acid products far exceed those for recombinant collagen, indicating a stronger safety profile for hyaluronic acid [25][26]. Group 4: Regulatory Environment - The article notes that the regulatory environment for brokerage reports is tightening, with recent inspections revealing issues in compliance and the need for better management of report quality and information sources [18][20]. - There is a growing concern about the potential for misleading information in brokerage reports, which could lead to regulatory actions against the firms involved if found to be in violation of established guidelines [21][22].

Core Viewpoint - The beauty blogger "Dr. Big Mouth" accused Giant Biological (02367.HK) of serious fraud regarding its Kefu Mei collagen essence, claiming that the actual content of recombinant collagen is only 0.0177% in the best-selling product, and that the key component "glycine" is missing [2][3][10]. Group 1: Accusations and Responses - The blogger questioned the legality of labeling recombinant collagen as a non-trace component when its actual content is below the regulatory threshold of 0.1% [3][10]. - Giant Biological issued a statement firmly denying the allegations, asserting that multiple tests showed collagen content greater than 0.1%, contradicting the blogger's claims [12][14]. - The company emphasized its adherence to scientific ethics and regulatory compliance, stating that all products are rigorously tested and verified [12][14]. Group 2: Product Composition Concerns - The blogger raised concerns about the absence of glycine in a product claiming to contain recombinant collagen, questioning the validity of calling it "recombinant collagen" [5][9]. - There were also questions about the marketing of a dipeptide molecule as "Mini small molecule collagen," suggesting potential misuse of scientific terminology [7]. Group 3: Market Performance and Investor Sentiment - Despite the controversies, Giant Biological has seen significant growth, reporting a revenue of 5.539 billion yuan in 2024, a year-on-year increase of 57.07%, and a net profit of 2.062 billion yuan, up 42.06% [22]. - The company has gained substantial attention from investors, with several funds heavily investing in its stock, indicating strong market confidence [24].

Core Viewpoint - The controversy surrounding the collagen product "Kefumei" from Giant Biological has escalated due to allegations of ingredient falsification, leading to a crisis of trust among investors and consumers [5][6][10]. Company Summary - Dr. Hao Yu published a report claiming that the collagen content in "Kefumei" is only 0.0177%, significantly below the stated minimum of 0.1%, and that key component glycine was not detected [5][10]. - Giant Biological quickly responded to the allegations, asserting that their products comply with regulatory standards and that they have commissioned multiple third-party testing agencies to verify the collagen content [12][15]. - The company emphasized that their products have passed strict regulatory reviews and that the testing methods used by Dr. Hao Yu are not recognized by industry standards [15][12]. - As of May 25, "Kefumei" has sold over 1 million units, contributing significantly to the company's revenue, with sales projected to reach 27.88 billion yuan and 45.42 billion yuan in 2023 and 2024, respectively [17][19]. Industry Summary - The incident highlights a broader issue within the recombinant collagen industry, where there is currently no unified testing standard, leading to discrepancies in results from different testing methods [22]. - The controversy reflects a struggle between technical standards and commercial interests, with the ultimate resolution depending on consumer trust and regulatory oversight [22]. - The need for transparency in testing and a shift from marketing-driven to technology-driven strategies is critical for the long-term success of companies in the recombinant collagen sector [22].

Core Viewpoint - The skincare brand Kefu Mei, under Giant Biological, strongly denies allegations of false advertising regarding the content of recombinant collagen in its products, asserting that the claims made by a beauty blogger are unfounded and based on non-standard testing methods [2][3][6]. Group 1: Allegations and Responses - A beauty blogger named "Big Mouth Doctor" accused Kefu Mei of having only 0.0177% of recombinant collagen in its product, which should theoretically be above 0.1% for non-trace ingredients, questioning the product's compliance with regulations [3][10]. - Kefu Mei responded by stating that their products undergo a three-tier verification system for quality control, ensuring no ingredient fraud or concealment occurs [6][9]. - The company presented its own testing results showing collagen content between 0.27% and 0.28%, contradicting the blogger's claims [6][7]. Group 2: Industry Standards and Legal Actions - Kefu Mei highlighted that there are currently no industry or national standards for the content of recombinant collagen, and the blogger's testing methods are not recognized by industry standards [8][9]. - The company plans to initiate legal action against the blogger for defamation, asserting that the allegations challenge the authority of regulatory bodies [9][10]. Group 3: Company Performance and Market Context - Giant Biological has experienced significant growth, with 2024 revenues reaching 5.54 billion yuan, a 57.2% increase year-on-year, and net profits of 2.06 billion yuan, up 42.4% [10]. - Kefu Mei's contribution to revenue exceeds 80%, with a year-on-year growth of 62.9%, positioning Giant Biological as one of the fastest-growing companies in the domestic beauty industry [10].

Core Viewpoint - The company firmly denies allegations regarding the absence of recombinant collagen in its products and plans to initiate legal action against the spreaders of false information [1][3]. Group 1: Company Response - The company issued a statement refuting claims of serious fraud and emphasized adherence to research ethics and industry responsibilities, ensuring compliance with relevant regulations [1]. - All products undergo a three-tier verification system, including raw material checks, production quality control, and finished product testing, to guarantee safety and reliability [1]. - The company has conducted multiple tests on its products, confirming that collagen content exceeds 0.1%, contradicting the alleged figure of 0.0177% [1][2]. Group 2: Third-Party Testing - To address consumer concerns, the company has engaged several authoritative third-party testing organizations to conduct further tests, with results to be published promptly [2]. - The testing methods referenced are based on the national pharmaceutical industry standard YY/T 1947-2025, as there are currently no industry or national standards for collagen content in cosmetics [2]. Group 3: Allegations and Legal Action - The company criticized the testing methods used in the allegations, stating they lack rigorous methodological validation and thus yield unreliable results [3]. - The company has gathered evidence against the malicious spread of false claims and will pursue legal action to protect its rights and the interests of consumers and investors [3]. - The company expressed its desire to focus on industry growth rather than engaging in a cycle of self-defense against organized smear campaigns [3].

Core Viewpoint - A social media influencer raised concerns about potential fraud by Juzhi Biotechnology regarding their collagen product, claiming that the detected collagen content was significantly lower than what was stated on the product label [2][3]. Group 1: Detection and Analysis - The influencer utilized high-precision HPLC amino acid quantification methods to test the collagen product, revealing that the detected collagen content was only 0.0177%, which is below the expected threshold of 0.1% for non-trace ingredients [2][3]. - The influencer's analysis indicated that glycine, a key component of collagen, was not detected in the sample, contradicting established knowledge that glycine constitutes one-third of collagen's amino acid residues [3]. Group 2: Company Response - In response to the allegations, Juzhi Biotechnology's brand Kefu Mei stated that their own testing showed collagen content exceeding 0.1%, with results of 0.27%, 0.27%, and 0.28% from multiple samples taken on May 24 [4]. - The company criticized the influencer's testing methods as not being recognized by industry standards and claimed that the influencer did not request the original collagen material for testing [4]. Group 3: Regulatory Context - A consumer previously reported adverse effects after using a product from Juzhi Biotechnology, leading to a separate investigation regarding the presence of epidermal growth factor (EGF), which is prohibited in cosmetics [4][5]. - The Shaanxi Provincial Drug Administration conducted inspections and found no evidence of EGF in the products, concluding that the company did not engage in illegal practices regarding EGF [5].

Group 1 - The National Internet Information Office is intensifying efforts to rectify online financial information chaos, closing accounts and websites that spread false information about the capital market and engage in illegal stock recommendations and cryptocurrency trading [1] Group 2 - Hong Kong's Chief Executive, John Lee, aims to leverage Hong Kong's geographical advantages and logistics infrastructure to establish it as a cross-border e-commerce logistics hub in the Greater Bay Area, focusing on digital transformation and data transaction facilitation [2] Group 3 - The China Securities Regulatory Commission has imposed fines exceeding 2 billion yuan on Tian Han and related companies for illegal stock transfers and false disclosures regarding "Aoyuan Meigu" [3] Group 4 - Trump has threatened tariffs on Samsung and other smartphone manufacturers, indicating that any phones made abroad and sold in the U.S. could face at least a 25% tariff, which may lead to industry restructuring and increased uncertainty for global manufacturers [7] Group 5 - Trump supports the acquisition of U.S. Steel by Japan's Nippon Steel, which is expected to create 70,000 jobs and generate $14 billion in economic benefits, indicating a significant shift in the U.S. steel industry [8] Group 6 - Dongfeng Motor and Huawei have signed a comprehensive strategic cooperation agreement to enhance collaboration in automotive intelligence and digitalization, aiming to strengthen China's position in the smart vehicle sector [9] Group 7 - Huawei's open-source HarmonyOS project has seen over 1,100 software and hardware products pass compatibility testing, reflecting Huawei's strong performance in the operating system sector [10][11] Group 8 - BYD has launched a promotional campaign for 22 models with discounts up to 53,000 yuan, aiming to accelerate the adoption of intelligent driving technology and market penetration [12]

Group 1 - The National Cyberspace Administration of China is intensifying efforts to rectify online financial information chaos, shutting down accounts and websites spreading false information about the capital market and engaging in illegal stock recommendations and cryptocurrency trading [2] Group 2 - Hong Kong Chief Executive John Lee aims to leverage Hong Kong's geographical advantages and logistics infrastructure to establish it as a cross-border e-commerce logistics hub in the Greater Bay Area, focusing on digital transformation and data flow arrangements [3] Group 3 - The China Securities Regulatory Commission has imposed fines exceeding 2 billion yuan on Tian Han and related companies for illegal stock transfers and false disclosures regarding "Aoyuan Meigu" [4] Group 4 - Trump has threatened tariffs on Samsung and other phone manufacturers, stating that any phones made abroad and sold in the U.S. should face at least a 25% tariff, which could lead to uncertainty in the global smartphone manufacturing industry [10] Group 5 - Dongfeng Motor Group and Huawei have signed a comprehensive strategic cooperation agreement to deepen collaboration in automotive intelligence and digitalization, aiming to enhance China's automotive industry's competitive edge [12] Group 6 - BYD has launched a promotional campaign offering discounts of up to 53,000 yuan on 22 models, aiming to accelerate the adoption of intelligent driving technology and market penetration [15]